Vietnam to purchase Spain's HIPRA COVID-19 vaccine


T&T PHARMA, a Vietnamese pharmaceutical joint stock company, has inked a contract to purchase 50 million doses of HIPRA, a COVID-19 vaccine produced by Spain's HYPRAHuman Health S.L.U. The EUR375 million contract was signed on September 11 during Vietnam National Assembly Chairman Vuong Dinh Hue's visit to Finland.

What – did the depopulation agenda for Vietnam get assigned to Spain?

About HIPRA's vaccine:

Hipra: First Spanish Covid-19 vaccine approved for human clinical trial

12 August - The Spanish Agency of Medicine and Health Products (AEMPS) authorized on Wednesday the first human clinical trial of the PHH-1V vaccine against Covid-19, developed by the Spanish pharmaceutical company Hipra, which is based in Amer in Girona province. This is the first time a Spanish Covid-19 vaccine has been approved for human trials.

Plans to produce 400 million doses of Spanish Covid-19 vaccine in 2022

Pedro Sanchez - center.

Spanish Prime Minister Pedro Sanchez visited HIPRA, underlining that the government will continue to offer its full support in the hope of obtaining a Spanish vaccine against Covid19. He stressed the importance of public-private alliances and of collaboration between all tiers of government in the fight against the pandemic.

Is Sanchez bent and a globalist puppet?

Looks like Spain is getting in on the lucrative action.

Also, they not only sold their version of the poison to Vietnam, they recently sold their Pfizer vaccines to New Zealand -

Life or Death: Pharmaceutical “Plandemic” Poisonous Vaccines, or the Healing of the Holy Spirit – Your choice


Spain’s Hipra gets green light for Phase II COVID vaccine trials

MADRID (Reuters) -Spain’s medicines agency has authorised Catalonia-based pharmaceutical group Hipra to test a COVID-19 vaccine it is developing on more than 1,000 volunteers, Prime Minister Pedro Sanchez said on Monday.

Hipra will carry out the so-called Phase II trial – the second stage of a three-round trial process – on volunteers at 10 hospitals around Spain, Sanchez said.

Speaking at an event to present how European Union recovery funds will be channelled into health investments, Sanchez described the vaccine development as “extraordinary news”.

“It demonstrates that Spain can position itself at the forefront of the response to COVID,” he said, adding that the government had given a 15 million euro ($17.17 million) grant to develop the drug.

Hipra, a pharmaceutical lab that mainly researches and manufactures veterinary vaccines, has been working on two COVID-19 shots.

One is based on the same RNA messenger technology used in shots made by Pfizer and Moderna, while the second, which has just received approval for trial, uses a recombinant protein like that of U.S. based drugmaker Novavax.

Hipra has said on its website that it anticipates being able to produce 600 million doses in 2022 and double that figure the following year.

Spain’s Hipra gets green light for Phase II COVID vaccine trials | 1330 & 101.5 WHBL